SCHEMBL30028263

SCHEMBL30028263

COc1cc(CCN)ccc1OCc1ccccc1

nearest known ligand 0.68

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.68
ATM Q13315 1/20 0.68
CYP1A2 P05177 1/20 0.64
CYP3A4 P08684 1/20 0.64
CYP2D6 P10635 1/20 0.64
CYP2C9 P11712 1/20 0.64
BLM P54132 1/20 0.64
MEN1 O00255 1/20 0.61
KMT2A Q03164 1/20 0.61
MTNR1A P48039 2/20 0.60
MTNR1B P49286 2/20 0.60
APP P05067 1/20 0.60
ABCB1 P08183 2/20 0.58
ABCG2 Q9UNQ0 1/20 0.58
BCHE P06276 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL67744 1.00 KDM4E (0.68) KDM4EATMCYP1A2CYP3A4CYP2D6
Hydrochloric Acid SCHEMBL1298567 0.98 KDM4E (0.66) KDM4EATMCYP1A2CYP3A4CYP2D6
SCHEMBL2742565 0.94 KDM4E (0.68) KDM4EATMCYP1A2CYP3A4CYP2D6
Hydrochloric Acid SCHEMBL17821823 0.93 KDM4E (0.66) KDM4EATMCYP1A2CYP3A4CYP2D6
SCHEMBL5209173 0.91 MTNR1A (0.64) KDM4EATMCYP1A2CYP3A4CYP2D6
SCHEMBL3272392 0.91 SLC2A1 (0.54) KDM4EATMCYP1A2CYP3A4CYP2D6
SCHEMBL31040310 0.90 KDM4E (0.54) KDM4EATMCYP1A2CYP3A4CYP2D6
Hydrochloric Acid SCHEMBL5628566 0.89 SLC2A1 (0.52) KDM4EATMCYP1A2CYP3A4CYP2D6
SCHEMBL3712764 0.88 MEN1 (0.60) KDM4ECYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL23206799 0.88 KDM4E (0.59) KDM4EATMCYP1A2CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250340555-A1 Tricyclic Fused Heterocyclic PDE3/4 Dual Inhibitor and Use Thereof XIZANG HAISCO PHARMACEUTICAL CO LTD (CN) 2025-11-06 US disclosed
EP-4606427-A2 TRICYCLIC FUSED HETEROCYCLIC PDE3/4 DUAL INHIBITOR AND USE THEREOF Xizang Haisco Pharmaceutical Co., Ltd. (CN) 2025-08-27 EP disclosed
US-20250059186-A1 Tricyclic Fused Heterocyclic PDE3/4 Dual Inhibitor and Use Thereof XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) 2025-02-20 US disclosed
EP-4450500-A1 TRICYCLIC FUSED HETEROCYCLIC PDE3/4 DUAL INHIBITOR AND USE THEREOF Xizang Haisco Pharmaceutical Co., Ltd. (CN) 2024-10-23 EP disclosed
CN-115260185-B Deuterated derivative of corydaline and stephanine and preparation method thereof 杨征 2024-09-24 CN disclosed
CN-115260185-A Deuterated derivatives of corydaline and stepholidine and preparation method thereof 杨征 2022-11-01 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250340555-A1 Tricyclic Fused Heterocyclic PDE3/4 Dual Inhibitor and Use Thereof PDE3A, PDE3B, PDE4A KDM4E 1093/4885ATM 3231/4885CYP1A2 997/4885
US-20250059186-A1 Tricyclic Fused Heterocyclic PDE3/4 Dual Inhibitor and Use Thereof PDE3A, PDE3B, PDE4A KDM4E 1093/4885ATM 3231/4885CYP1A2 997/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.